Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Immunogenicity Study of GSK Biologicals' Investigational Vaccination Regimen Malaria Vaccine 257049, When Incorporated Into an Expanded Program on Immunization (EPI) Regimen That Includes Tritanrix HepB/Hib, OPV, Measles and Yellow Fever Vaccination in Infants

NCT00436007 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00436007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00436007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Immunogenicity Study of GSK Biologicals' Investigational Vaccination Regimen Malaria Vaccine 257049, When Incorporated Into an Expanded Program on Immunization (EPI) Regimen That Includes Tritanrix HepB/Hib, OPV, Measles and Yellow Fever Vaccination in Infants
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2007
Completion date
October 7, 2009
Enrollment
511 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

malaria